Abstract

Background: PAX5 is a transcriptional factor that considered as one of the key molecules for regulation of many cancer associated genes.
Objectives: The aim of this study was to examine status of PAX5 in human breast carcinoma through assessment its relation to CD19 expression.
Patients and Methods: PAX5 and CD19 expression in breast tissue samples were measured by RT-PCR in 90 female breast specimens including 50 cases of invasive ductal carcinoma, 25 cases with fibroadenoma and 15 non-pathological breast tissue as control group.
Results: The best cut-off values for the investigated markers were determined by ROC curve. PAX5 at 0.05 was 92.0% sensitivity and 92.5% specificity while CD19 at 0.62 was 94.0% sensitivity and 95.0% specificity. Moreover, positivity rates and mean levels for PAX5 and CD19 showed significant difference among the three investigated groups (p < 0.001). PAX5 was higher in advanced grades (p< 0.05), stages (p< 0.01) and positive estrogen tumor receptors (p< 0.05). Moreover, PAX5 showed a significant positive correlation with CD19.
Conclusion: PAX5 expression may consider a potential biomarker in breast cancer having a possible role in breast cancer tumorgenesis through CD19.

Key words: Keywords: Breast cancer; CD19 and PAX5.